

ASX Announcement

For immediate release

17 March 2025

Appointment of Voluntary Administrators

Bluechiip I Limited (ASX:"BCT" or "the Company") advises that the Company has entered Voluntary Administration with the appointment of Manuel Hanna of Romanis Cant as Administrator of Bluechiip Limited pursuant to a resolution of the Company's directors effective 17 March 2025.

The Administrator is undertaking an assessment of the Company's business operations and financial affairs. During the Voluntary Administration period, all listed securities will remain suspended. Shareholders should refer to the information sheet on insolvency for shareholders provided by ASIC at https://asic.gov.au/regulatory-resources/insolvency/insolvency-for-investors-and-shareholders/.

Authorised for release by the Board

END

Authorised for release by the Bluechiip Limited Board

For more information, please contact:

Andrew McLellan Iain Kirkwood

Managing Director / CEO Non-executive Chair

Ph: +61 457 823 470 Mob: 0408 473 496

andrew.mclellan@bluechiip.com

About Bluechiip Limited

Bluechiip understands that every biological sample – stem cells, blood, eggs, sperm and other biospecimens – is critical, so our objective is to manage each one with optimal quality in the most efficient way. Bluechiip's Advanced Sample Management Solution is the only one that provides sample temperature with ID in cryogenic environments, driving productivity and improving quality. Bluechiip's solution delivers confidence in every sample.

Bluechiip's unique patented technology is a MEMS-based wireless tracking solution that contains no electronics. It represents a generational change from current tracking methods such as labels (hand-written and preprinted), barcodes (linear and 2D), and Radio Frequency Identification. Bluechiip tags are either embedded or manufactured into storage products such as vials or bags. Each product is easily identified and critical information, such as sample temperature, detected by readers and stored in the Bluechiip software. In addition to functioning in extreme temperatures, the Bluechiip® Advanced Sample management solution can survive autoclaving, gamma irradiation sterilization, humidification, centrifuging, cryogenic storage and frosting.

Bluechiip listed on the ASX in June 2011. Since then, it has significantly developed its technology. Today Bluechiip's Technology has applications in healthcare, including in cryogenic storage facilities (biobanks and biorepositories), pathology, clinical trials and forensics. Other key markets include cold-chain logistics/supply chain, security/defence, industrial/manufacturing and aerospace/aviation.

Bluechiip: Delivering confidence in every sample.

Further information is available at www.bluechiip.com